FDA Status
Not FDA-Approved (US)
Approved in Russia (2009)
Claimed Benefits
- Anxiolytic (anti-anxiety)
- Mild psychostimulant
- Immunomodulation
Clinical Evidence
4
Human Trials
Approved (Russia)
Highest Phase
Demonstrated anxiolytic efficacy equivalent to benzodiazepine medazepam in GAD patients, without sedation or cognitive dulling.
Read Full Deep Dive
Mechanism, dosing, vendor pricing, and full research citations